First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial
First-line nivolumab plus ipilimumab has shown improved overall survival in patients with advanced non-small-cell lung cancer (NSCLC) The most common grade 3–4 treatment-related adverse events were neutropenia, anaemia, diarrhoea, and increased lipase. The most common grade 3–4 treatment-related adverse events were neutropenia, anaemia, diarrhoea, and increased lipase. The risk-benefit profile of this regimen is considered favourable.
